|
Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950). |
|
|
Honoraria - Lilly; PharmaMar; Takeda |
Consulting or Advisory Role - Bayer; Epizyme; Immune Design; Lilly; MaxiVax; PharmaMar |
Research Funding - Advenchen Laboratories (Inst); Amgen (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst) |
Travel, Accommodations, Expenses - PharmaMar |
|
|
Consulting or Advisory Role - Adaptimmune (Inst); Blueprint Medicines (Inst); Deciphera (Inst); Eisai (Inst); Ellipses Pharma (Inst); Genmab (Inst); Intellisphere (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Plexxikon (Inst); SERVIER (Inst); Transgene (Inst) |
Research Funding - Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); CoBioRes NV (Inst); Eisai (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Lilly (Inst); Novartis (Inst); PharmaMar (Inst); Plexxikon (Inst) |
|
|
Consulting or Advisory Role - Adaptimmune; Blueprint Medicines; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Immune Design; Lilly; Merck |
|
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Agios; Epizyme; Ignyta; Janssen; Lilly; Novartis |
Travel, Accommodations, Expenses - Epizyme; GenMab; Janssen; Lilly; Xencor |
|
|
Research Funding - Acerta Pharma (Inst); Aduro Biotech (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Epizyme (Inst); Lilly (Inst); Polaris (Inst); Trizell (Inst) |
|
|
Honoraria - Eisai; Lilly; Novartis |
Consulting or Advisory Role - Eisai |
Research Funding - Eisai; Epizyme |
Travel, Accommodations, Expenses - Eisai |
|
|
Honoraria - Bayer; Daiichi Sankyo; Epizyme; Lilly; Novartis; Roche |
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche |
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - 2nd.MD; Advance Medical; Agios; Grand Rounds Health; InfiniteMD |
Research Funding - Agios (Inst); Bavarian Nordic; Boston Biomedical (Inst); CBA Research (Inst); Eisai (Inst); Epizyme (Inst); Macrogenics (Inst); Merck KGaA (Inst); PharmaMar (Inst); Plexxikon (Inst) |
|
|
Stock and Other Ownership Interests - Portola Pharmaceuticals |
Consulting or Advisory Role - EMD Serono; Epizyme; Janssen |
Research Funding - AADi (Inst); Advenchen Laboratories (Inst); Epizyme (Inst); Lilly (Inst); MabVax (Inst); Medivation/Pfizer (Inst); Morphotek (Inst); Novartis (Inst) |
|
|
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); BTG (Inst); CBA Pharma (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); Genmab (Inst); Gradalis (Inst); Immune Design (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Philogen (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); TRACON Pharma (Inst) |
Travel, Accommodations, Expenses - Immune Design |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Epizyme |
|
|
|
Stock and Other Ownership Interests - Epizyme |
|
|
|
Stock and Other Ownership Interests - Epizyme |
|
|
Honoraria - Amgen; Bayer; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics; Springworks Therapeutics; TRACON Pharma |
Consulting or Advisory Role - Amgen; Bayer; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics; Springworks Therapeutics |
|
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics |
Other Relationship - Desmoid Tumor Research Foundation |